Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.

• Abstract: Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.
• Authors: Lisa M Neff, Michelle Weil, Alan Cole, Thomas R Hedges, William Shucart, Donald Lawrence, Jay-Jiguang Zhu, Arthur S Tischler, Ronald M Lechan (Affiliation: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Tufts-New England Medical Center, Boston, MA 02111, USA.)
• Journal: Pituitary (Pituitary) Vol. 10 Issue 1 Pg. 81-6 ( 2007) ISSN: 1386-341X [Print] United States
• PMID: 17285366 (Publication Type: Case Reports, Journal Article)

Chemical References

• Dopamine Agonists
• Dacarbazine
• temozolomide
• Prolactin

Topics

• Dacarbazine (adverse effects, analogs & derivatives, therapeutic use)
• Dopamine Agonists (therapeutic use)
• Drug Resistance, Neoplasm
• Female
• Humans
• Middle Aged
• Pituitary Neoplasms (diagnosis, drug therapy)
• Prolactin (blood)
• Prolactinoma (diagnosis, drug therapy)